Summary
NanoViricides inks regulatory services deal to advance orphan drug strategy for antiviral NV-387
NanoViricides (NYSE-A:NNVC) said on Monday it signed a master services agreement with regulatory consulting firm Only Orphans Cote LLC to support the company's orphan drug strategy for its broad-spectrum antiviral candidate NV-387. The firm, founded by former US Food and Drug Administration official Dr Timothy Cote, will help develop and prosecute orphan drug designation applications for NV-387 at the FDA's Office of Orphan Products, NanoViricides said.
NanoViricides raises cash, moves broad-spectrum antiviral NV-387 into Phase II trials
NanoViricides (NYSE-A:NNVC) is advancing its broad-spectrum antiviral NV-387, backed by new financing that strengthens its balance sheet and supports regulatory progress toward Phase II trials for monkeypox in Central Africa. In its quarterly report for the quarter ended September 30, 2025, the clinical-stage biotech company said NV-387 is engineered to resist viral escape.
NanoViricides closes $6M offering to fund operations
NanoViricides (NYSE-A:NNVC) said on Thursday it had closed a $6 million registered direct offering with a single healthcare institutional investor to support working capital and general corporate purposes. The Connecticut-based biotechnology company sold about 3.57 million shares of common stock, or equivalents, at $1.68 per share.
Nanoviricides Inc. (NNVC) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Nanoviricides Inc. ever had a stock split?
Nanoviricides Inc. Profile
| Biotechnology Industry | Healthcare Sector | Anil R. Diwan CEO | AMEX Exchange | 630087302 CUSIP |
| US Country | 7 Employees | - Last Dividend | 24 Sep 2019 Last Split | 26 Oct 2005 IPO Date |
Overview
NanoViricides, Inc. is a pioneering clinical stage nano-biopharmaceutical company focused on the discovery, development, and commercialization of novel drugs for the treatment of viral infections. Founded in 2005 and based in Shelton, Connecticut, the company leverages its proprietary nanoviricide® technology to craft innovative therapies aimed at various viral diseases. This technology employs biomimetic strategies to create drugs that mimic natural virus-binding mechanisms, allowing for targeted delivery of antiviral payloads directly into infected cells while sparing healthy ones. Through its advanced research and clinical trials, NanoViricides aims to bring new solutions to market that address unmet medical needs in the management of viral infections.
Products and Services
The following are the key products and services developed by NanoViricides, Inc.:
- NV-CoV-2, Nanoviricide Drug
This drug is currently undergoing phase 1a/1b clinical trials for the treatment of COVID-19. It represents the company's commitment to addressing the global pandemic by harnessing their nanoviricide technology to target and neutralize the virus.
- NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies
Designed specifically for pediatric cases, these semi-solid fixed-dose forms are in phase 1a/1b human clinical trials. They allow for body-weight-based dose titration, offering a potentially safer and more effective treatment option for children suffering from COVID-19.
- NV-CoV-2 Solution for Injection, Infusion, and Inhalation
This versatile formulation is aimed at treating severe cases of COVID-19 that have not yet required hospitalization. It can be administered as an injection or delivered directly into the lungs using a nebulizer. This method seeks to directly target the primary site of infection by many respiratory viruses, potentially offering a significant advantage in treating diseases that can lead to severe pneumonia.
- Nanoviricide Biomimetic Platform Technology
The cornerstone of NanoViricides' offerings, this platform technology is designed to carefully mimic the envelope of virus particles. It facilitates the delivery of antiviral drugs directly into infected cells, disrupting the virus's replication cycle with minimal toxicity to healthy cells. This technology represents a broad-spectrum approach capable of targeting a variety of enveloped viral infections beyond COVID-19, including influenza, RSV, and more.
Contact Information
